ReviewMolecules (Basel, Switzerland)2025

Focus on PD-1/PD-L1-Targeting Antibodies in Colorectal Cancer: Are There Options Beyond Dostarlimab, Nivolumab, and Pembrolizumab? A Comprehensive Review.

Mateusz Kciuk et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.